엑소좀 진단 및 치료 시장 규모, 점유율, 성장 분석 : 제품별, 용도별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Exosome Diagnostic and Therapeutic Market size was valued at USD 90.5 Million in 2024 and is poised to grow from USD 99.28 Million in 2025 to USD 208.22 Million by 2033, growing at a CAGR of 9.7% during the forecast period (2026-2033).

The global exosome diagnostics and therapeutics market is witnessing robust growth, fueled by heightened investments in precision medicine and a rising preference for less invasive diagnostic techniques. Innovations in exosome-based technologies are enhancing early disease detection, particularly for cancer, neurological disorders, and cardiovascular issues. The proliferation of research initiatives and clinical trials is further accelerating the advancement and commercialization of exosome-derived solutions in key markets. However, the sector faces challenges such as the absence of standardized protocols for exosome isolation and characterization, along with regulatory and validation hurdles for clinical applications. To ensure long-term market sustainability, it is crucial to foster collaborative research efforts and establish clear standards to address these technical and regulatory obstacles effectively.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Exosome Diagnostic and Therapeutic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Exosome Diagnostic and Therapeutic Market Segments Analysis

Global Exosome Diagnostic and Therapeutic Market is segmented by Products, Applications, End Users and region. Based on Products, the market is segmented into Instruments, Software and Reagents & Kits. Based on Applications, the market is segmented into Diagnostics and Therapeutic. Based on End Users, the market is segmented into Hospitals, Cancer Institutes, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Exosome Diagnostic and Therapeutic Market

One of the key market drivers for the global exosome diagnostic and therapeutic market is the increasing prevalence of chronic diseases, including cancer and neurodegenerative disorders, which demand innovative diagnostic and treatment options. Exosomes, as key mediators of intercellular communication, offer significant potential in biomarker discovery and targeted therapies, leading to improved diagnostic accuracy and patient-specific treatment approaches. Furthermore, advancements in nanotechnology and molecular biology are facilitating the development of exosome-based products, enhancing their utility in clinical applications. This growing recognition of exosomes in disease management is propelling research investments and fostering collaboration among pharmaceutical and biotechnology companies.

Restraints in the Global Exosome Diagnostic and Therapeutic Market

One key market restraint for the global exosome diagnostic and therapeutic market is the high costs associated with the development and commercialization of exosome-based products. The complexity of isolating, characterizing, and utilizing exosomes for clinical applications demands significant financial investment in research, technology, and regulatory compliance. Additionally, the lack of standardized protocols and methodologies for exosome analysis can hinder widespread adoption and increase costs further. This financial burden can limit the participation of smaller biotech firms and academic institutions, ultimately slowing innovation and reducing the availability of exosome-based diagnostics and therapies in the marketplace.

Market Trends of the Global Exosome Diagnostic and Therapeutic Market

The Global Exosome Diagnostic and Therapeutic market is witnessing a significant trend towards the integration of artificial intelligence to enhance exosome assessment. This technological advancement facilitates the analysis of complex datasets, thereby accelerating the identification of disease biomarkers with improved accuracy. The emergence of AI-driven tools is streamlining data interpretation and optimizing therapeutic targeting, particularly in critical fields such as oncology and neurology. This trend is contributing to more effective decision-making processes and supports the development of personalized treatment pathways, ultimately driving innovation and growth within the exosome market as stakeholders increasingly leverage AI capabilities for better clinical outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Exosome Diagnostic and Therapeutic Market Size by Products & CAGR (2026-2033)

• Market Overview
• Instruments
• Software
• Reagents & Kits

Global Exosome Diagnostic and Therapeutic Market Size by Applications & CAGR (2026-2033)

• Market Overview
• Diagnostics
• Therapeutic

Global Exosome Diagnostic and Therapeutic Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer Institutes
• Diagnostic Centers
• Others

Global Exosome Diagnostic and Therapeutic Market Size & CAGR (2026-2033)

• North America (Products, Applications, End Users)
  • US
  • Canada
• Europe (Products, Applications, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Products, Applications, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Products, Applications, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Products, Applications, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evox Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capricor Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aegle Therapeutics Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Codiak BioSciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ILIAS Biologics Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aruna Bio (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coya Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exopharm Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Direct Biologics LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Miltenyi Biotec (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoView Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EVerZom (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• INOVIQ Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• System Biosciences (SBI) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations